A citation-based method for searching scientific literature

Jan J Bandolik, Alexandra Hamacher, Christian Schrenk, Robin Weishaupt, Matthias U Kassack. Int J Mol Sci 2019
Times Cited: 18







List of co-cited articles
83 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Histone Deacetylase Inhibitors as Anticancer Drugs.
Tomas Eckschlager, Johana Plch, Marie Stiborova, Jan Hrabeta. Int J Mol Sci 2017
593
38


Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780.
Laura H Engelke, Alexandra Hamacher, Peter Proksch, Matthias U Kassack. J Cancer 2016
45
27

Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1.
Eva M Gosepath, Niels Eckstein, Alexandra Hamacher, Kati Servan, Georg von Jonquieres, Hermann Lage, Balazs Györffy, Hans D Royer, Matthias U Kassack. Int J Cancer 2008
55
22




Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors.
D Diedrich, A Hamacher, C G W Gertzen, L A Alves Avelar, G J Reiss, T Kurz, H Gohlke, M U Kassack, F K Hansen. Chem Commun (Camb) 2016
32
16

Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
Katharina Stenzel, Alexandra Hamacher, Finn K Hansen, Christoph G W Gertzen, Johanna Senger, Viktoria Marquardt, Linda Marek, Martin Marek, Christophe Romier, Marc Remke,[...]. J Med Chem 2017
30
16

HDAC family: What are the cancer relevant targets?
Olaf Witt, Hedwig E Deubzer, Till Milde, Ina Oehme. Cancer Lett 2009
730
16

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.
Dmitri Pchejetski, Albandri Alfraidi, Keith Sacco, Heba Alshaker, Aun Muhammad, Leonardo Monzon. J Cancer Res Clin Oncol 2016
16
18


Molecular mechanisms of cisplatin resistance.
L Galluzzi, L Senovilla, I Vitale, J Michels, I Martins, O Kepp, M Castedo, G Kroemer. Oncogene 2012
16

Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
Marc Pflieger, Alexandra Hamacher, Taner Öz, Nadine Horstick-Muche, Benedikt Boesen, Christian Schrenk, Matthias U Kassack, Thomas Kurz. Bioorg Med Chem 2019
6
50

Expression profile of class I histone deacetylases in human cancer tissues.
Masamune Nakagawa, Yoshinao Oda, Takashi Eguchi, Shin-Ichi Aishima, Takashi Yao, Fumihito Hosoi, Yuji Basaki, Mayumi Ono, Michihiko Kuwano, Masao Tanaka,[...]. Oncol Rep 2007
243
16

Histone deacetylases (HDACs): characterization of the classical HDAC family.
Annemieke J M de Ruijter, Albert H van Gennip, Huib N Caron, Stephan Kemp, André B P van Kuilenburg. Biochem J 2003
16

Deacetylation of p53 modulates its effect on cell growth and apoptosis.
J Luo, F Su, D Chen, A Shiloh, W Gu. Nature 2000
645
16

HDAC Inhibitors in Acute Myeloid Leukemia.
Edurne San José-Enériz, Naroa Gimenez-Camino, Xabier Agirre, Felipe Prosper. Cancers (Basel) 2019
65
16


Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Andrew J Wilson, Kofi Sarfo-Kantanka, Toby Barrack, Alexandra Steck, Jeanette Saskowski, Marta A Crispens, Dineo Khabele. Gynecol Oncol 2016
23
16

A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening.
Thomas Ciossek, Heiko Julius, Heike Wieland, Thomas Maier, Thomas Beckers. Anal Biochem 2008
26
11

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
Katrina J Falkenberg, Ricky W Johnstone. Nat Rev Drug Discov 2014
996
11

Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
Benjamin E L Lauffer, Robert Mintzer, Rina Fong, Susmith Mukund, Christine Tam, Inna Zilberleyb, Birgit Flicke, Allegra Ritscher, Grazyna Fedorowicz, Roxanne Vallero,[...]. J Biol Chem 2013
241
11

Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
Claire Bonfils, Ann Kalita, Marja Dubay, Lillian L Siu, Michael A Carducci, Gregory Reid, Robert E Martell, Jeffrey M Besterman, Zuomei Li. Clin Cancer Res 2008
72
11

HDAC inhibitor-based therapies: can we interpret the code?
Maria New, Heidi Olzscha, Nicholas B La Thangue. Mol Oncol 2012
239
11

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Madhusoodanan Mottamal, Shilong Zheng, Tien L Huang, Guangdi Wang. Molecules 2015
437
11

Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
Viktoria Krieger, Alexandra Hamacher, Christoph G W Gertzen, Johanna Senger, Martijn R H Zwinderman, Martin Marek, Christophe Romier, Frank J Dekker, Thomas Kurz, Manfred Jung,[...]. J Med Chem 2017
22
11


Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Aline Kaletsch, Maria Pinkerneil, Michèle J Hoffmann, Ananda A Jaguva Vasudevan, Chenyin Wang, Finn K Hansen, Constanze Wiek, Helmut Hanenberg, Christoph Gertzen, Holger Gohlke,[...]. Clin Epigenetics 2018
39
11

The epigenomics of cancer.
Peter A Jones, Stephen B Baylin. Cell 2007
11

Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Günter Niegisch, Judith Knievel, Annemarie Koch, Christiane Hader, Ute Fischer, Peter Albers, Wolfgang A Schulz. Urol Oncol 2013
55
11

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Katharina Gohr, Alexandra Hamacher, Laura H Engelke, Matthias U Kassack. BMC Cancer 2017
44
11

The tetrahydroxanthone-dimer phomoxanthone A is a strong inducer of apoptosis in cisplatin-resistant solid cancer cells.
Chenyin Wang, Laura Engelke, David Bickel, Alexandra Hamacher, Marian Frank, Peter Proksch, Holger Gohlke, Matthias U Kassack. Bioorg Med Chem 2019
7
28

The Role of Resveratrol in Cancer Therapy.
Jeong-Hyeon Ko, Gautam Sethi, Jae-Young Um, Muthu K Shanmugam, Frank Arfuso, Alan Prem Kumar, Anupam Bishayee, Kwang Seok Ahn. Int J Mol Sci 2017
302
11

Erasers of histone acetylation: the histone deacetylase enzymes.
Edward Seto, Minoru Yoshida. Cold Spring Harb Perspect Biol 2014
853
11

Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
Baoyuan Zhang, Junfang Lyu, Eun Ju Yang, Yifan Liu, Changjie Wu, Lakhansing Pardeshi, Kaeling Tan, Qiang Chen, Xiaoling Xu, Chu-Xia Deng,[...]. Acta Pharm Sin B 2020
16
12

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
W Weichert, A Röske, V Gekeler, T Beckers, C Stephan, K Jung, F R Fritzsche, S Niesporek, C Denkert, M Dietel,[...]. Br J Cancer 2008
362
11

Targeting Class I Histone Deacetylases in a "Complex" Environment.
Christopher J Millard, Peter J Watson, Louise Fairall, John W R Schwabe. Trends Pharmacol Sci 2017
87
11

Crystal structure of the nucleosome core particle at 2.8 A resolution.
K Luger, A W Mäder, R K Richmond, D F Sargent, T J Richmond. Nature 1997
11

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Ailsa J Frew, Ricky W Johnstone, Jessica E Bolden. Cancer Lett 2009
185
11

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.
I Rettig, E Koeneke, F Trippel, W C Mueller, J Burhenne, A Kopp-Schneider, J Fabian, A Schober, U Fernekorn, A von Deimling,[...]. Cell Death Dis 2015
102
11

Histone deacetylase 8 in neuroblastoma tumorigenesis.
Ina Oehme, Hedwig E Deubzer, Dennis Wegener, Diana Pickert, Jan-Peter Linke, Barbara Hero, Annette Kopp-Schneider, Frank Westermann, Scott M Ulrich, Andreas von Deimling,[...]. Clin Cancer Res 2009
270
11

DNA methylation and its basic function.
Lisa D Moore, Thuc Le, Guoping Fan. Neuropsychopharmacology 2013
11

HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Yixuan Li, Edward Seto. Cold Spring Harb Perspect Med 2016
505
11

Histone deacetylase inhibitors: molecular mechanisms of action.
W S Xu, R B Parmigiani, P A Marks. Oncogene 2007
11


Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Yoshihiro Minamiya, Takashi Ono, Hajime Saito, Naoko Takahashi, Manabu Ito, Satoru Motoyama, Junichi Ogawa. Tumour Biol 2010
30
11

The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Øystein Helland, Mihaela Popa, Katharina Bischof, Bjørn Tore Gjertsen, Emmet McCormack, Line Bjørge. PLoS One 2016
19
11

Anticancer activities of histone deacetylase inhibitors.
Jessica E Bolden, Melissa J Peart, Ricky W Johnstone. Nat Rev Drug Discov 2006
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.